# Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

> **NCT01438775** · PHASE3 · COMPLETED · sponsor: **Nymox Corporation** · enrollment: 192 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** NX-1207

## Key facts

- **NCT ID:** NCT01438775
- **Lead sponsor:** Nymox Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2014-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01438775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01438775, "Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01438775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*